Immunocore (IMCR) Scheduled to Post Quarterly Earnings on Thursday

Immunocore (NASDAQ:IMCR) will be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Immunocore to post earnings of ($0.45) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The business had revenue of $70.30 million during the quarter, compared to the consensus estimate of $70.72 million. During the same period last year, the business posted ($0.35) earnings per share. The firm’s quarterly revenue was up 27.6% on a year-over-year basis. On average, analysts expect Immunocore to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunocore Stock Up 2.3 %

Shares of IMCR stock traded up $0.86 during trading hours on Tuesday, reaching $37.93. The company had a trading volume of 164,040 shares, compared to its average volume of 592,362. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -30.39 and a beta of 0.75. The company has a debt-to-equity ratio of 1.22, a current ratio of 5.96 and a quick ratio of 5.94. Immunocore has a 12 month low of $33.04 and a 12 month high of $76.98. The business has a fifty day simple moving average of $39.18 and a 200-day simple moving average of $54.70.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Leerink Partnrs reissued an “outperform” rating on shares of Immunocore in a research report on Monday, April 29th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, June 5th. JPMorgan Chase & Co. cut their price objective on Immunocore from $70.00 to $66.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 10th. Mizuho reduced their price objective on Immunocore from $90.00 to $88.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $81.00 target price on shares of Immunocore in a research note on Monday, June 3rd. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and an average target price of $83.09.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.